Holen Sie sich die Stockscreener-App
1.15
0.86%
-0.01
Schlusskurs vom Vortag:
$1.16
Offen:
$1.17
24-Stunden-Volumen:
570.65K
Relative Volume:
0.48
Marktkapitalisierung:
$70.67M
Einnahmen:
$5.03M
Nettoeinkommen (Verlust:
$-185.41M
KGV:
-0.3722
EPS:
-3.09
Netto-Cashflow:
$-139.79M
1W Leistung:
-2.13%
1M Leistung:
-12.88%
6M Leistung:
-32.35%
1J Leistung:
-55.85%
1-Tages-Spanne:
$1.12
$1.1914
1-Wochen-Bereich:
$1.09
$1.22
52-Wochen-Spanne:
$1.09
$3.78
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Firmenname
Pliant Therapeutics Inc
Sektor
Branche
Telefon
650-481-6770
Adresse
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare PLRX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.15 | 71.28M | 5.03M | -185.41M | -139.79M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.24 | 117.59B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
778.97 | 79.81B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
834.55 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.28 | 42.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
351.27 | 39.11B | 4.98B | 69.60M | 525.67M | 0.5198 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-03-04 | Fortgesetzt | Cantor Fitzgerald | Neutral |
| 2025-03-04 | Herabstufung | Needham | Buy → Hold |
| 2025-03-03 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-03-03 | Herabstufung | Stifel | Buy → Hold |
| 2025-02-10 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2025-02-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-02-10 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-02-10 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-02-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-02-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-10 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-05-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-04-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Buy |
| 2022-12-07 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-07-20 | Eingeleitet | SVB Leerink | Outperform |
| 2022-05-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-12-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-24 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-11-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-20 | Eingeleitet | BTIG Research | Buy |
| 2021-04-05 | Eingeleitet | Citigroup | Buy |
| 2020-06-29 | Eingeleitet | Citigroup | Buy |
| 2020-06-29 | Eingeleitet | Cowen | Outperform |
| 2020-06-29 | Eingeleitet | Needham | Buy |
| 2020-06-29 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Pliant Therapeutics Inc Aktie (PLRX) Neueste Nachrichten
Dividend Watch: What is the Moat Score of Pliant Therapeutics IncMarket Performance Recap & Expert Curated Trade Ideas - baoquankhu1.vn
Idiopathic Pulmonary Fibrosis Market: Expanding Revenue - openPR.com
Aug Analyst Calls: Is GENC on track to beat earningsQuarterly Risk Review & High Conviction Buy Zone Alerts - baoquankhu1.vn
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Short Interest Up 21.0% in January - MarketBeat
Portfolio Shifts: Is Pliant Therapeutics Inc. a potential multi baggerJuly 2025 Levels & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Weekly Earnings: How cyclical is Pliant Therapeutics Incs revenue streamExit Point & Scalable Portfolio Growth Methods - baoquankhu1.vn
Breakout Zone: Why is Pliant Therapeutics Inc stock going upJuly 2025 Macro Moves & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Rating of “Reduce” from Analysts - Defense World
Citadel Advisors LLC Acquires Additional Shares in Pliant Therapeutics Inc - GuruFocus
Quarterly Earnings: Is Pliant Therapeutics Inc a stock for growth or value investorsJuly 2025 Levels & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
What’s the beta of Pliant Therapeutics Inc. stockQuarterly Trade Report & Entry Point Confirmation Signals - mfd.ru
Pliant Therapeutics COO Kuo Minnie Sells $8853 in Shares By Investing.com - Investing.com UK
Pliant Therapeutics CHRO Cheung sells $9.6k in stock By Investing.com - Investing.com Nigeria
Bernard Coulie Sells 89,375 Shares of Pliant Therapeutics (NASDAQ:PLRX) Stock - MarketBeat
Pliant Therapeutics CHRO Cheung sells $9.6k in stock - Investing.com
Pliant therapeutics CFO Cummings sells $30,722 in stock By Investing.com - Investing.com Canada
Pliant therapeutics CEO Coulie sells $114k in shares By Investing.com - Investing.com Canada
Pliant therapeutics CEO Coulie sells $114k in shares - Investing.com
Pliant Therapeutics COO Kuo Minnie Sells $8853 in Shares - Investing.com
Aug Analyst Calls: Does Costamare Bulkers Holdings Limited stock reflect fundamentalsJobs Report & Verified Momentum Stock Alerts - baoquankhu1.vn
Analysis Recap: Is Pliant Therapeutics Inc benefiting from interest rate changesJuly 2025 WrapUp & Weekly High Momentum Picks - baoquankhu1.vn
Pliant Therapeutics Reports Improved Q3 2025 Results - MSN
Breakout Move: Whats the beta of Pliant Therapeutics Inc stock2025 Technical Patterns & AI Powered Market Entry Strategies - baoquankhu1.vn
Risk Check: What sentiment indicators say about Pliant Therapeutics Inc stockEarnings Risk Summary & Reliable Volume Spike Alerts - Bộ Nội Vụ
Pliant Therapeutics CFO sells $225,679 in stock - MSN
Is Pliant Therapeutics Inc. (9PT) stock prepared for digital transitionJuly 2025 Big Picture & Short-Term High Return Strategies - ulpravda.ru
Retail Trends: Is Pliant Therapeutics Inc. (9PT) stock worth holding before Fed meetingBreakout Watch & Safe Entry Zone Tips - Улправда
Can Pliant Therapeutics Inc. stock double in next 5 yearsStability vs Neutral Overview & HOKA model picks for your routine - Улправда
Will Pliant Therapeutics Inc. (9PT) stock beat revenue estimates2025 Biggest Moves & Daily Growth Stock Investment Tips - Улправда
Why retail investors pile into Pliant Therapeutics Inc. stockAnalyst Downgrade & Safe Swing Trade Setups - Улправда
Is Pliant Therapeutics Inc. (9PT) stock worth holding before Fed meetingBreakout Watch & Safe Entry Zone Tips - Улправда
How Pliant Therapeutics Inc. stock compares to market leadersBear Alert & Free Verified High Yield Trade Plans - Улправда
Aug Rallies: Can Pliant Therapeutics Inc. stock double in next 5 yearsJuly 2025 Chart Watch & Expert Approved Trade Ideas - Улправда
S P Trends: Can Pliant Therapeutics Inc. stock double in next 5 yearsJuly 2025 Intraday Action & Fast Moving Stock Watchlists - Улправда
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Average Rating of "Reduce" by Analysts - MarketBeat
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Average Rating of “Reduce” by Analysts - Defense World
NLC India Limited Breakout Confirmed by Volume MetricsResistance Breakout Alerts & Double Or Triple Profits - earlytimes.in
Weekly Earnings: What market sentiment indicators show for Pliant Therapeutics Inc 9PT stockWeekly Stock Analysis & Consistent Return Investment Signals - moha.gov.vn
What analysts say about Pliant Therapeutics Inc stockHigh Frequency Trading Trends & Free Triple Digit Wealth Increase - earlytimes.in
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Short Interest Down 20.3% in December - MarketBeat
How Pliant Therapeutics Inc 9PT stock trades pre earnings2025 Buyback Activity & Daily Volume Surge Signals - moha.gov.vn
Pliant Therapeutics announces departure of chief medical officer - MSN
Pliant Therapeutics appoints Minnie Kuo as COO - MSN
Pliant Therapeutics, Inc.(NasdaqGS: PLRX) dropped from NASDAQ Biotechnology Index - marketscreener.com
Pliant Therapeutics appoints Minnie Kuo as chief operating officer By Investing.com - Investing.com Nigeria
Finanzdaten der Pliant Therapeutics Inc-Aktie (PLRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.09%
2.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):